Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082840 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SIGMAR1MAPK1GFERSMN1; SMN2 | |
| SCHEMBL27189896 | 0.86 | ALDH1A1 (0.54) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL566005 | 0.85 | TSHR (0.61) | ALDH1A1MEN1KMT2ASIGMAR1HTT | |
| SCHEMBL28443002 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL4581466 | 0.84 | ALDH1A1 (0.71) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL6355304 | 0.84 | ALDH1A1 (0.71) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL1080422 | 0.83 | ALDH1A1 (0.57) | ALDH1A1CA12CA2CA9MEN1 | |
| SCHEMBL4810357 | 0.81 | SMN1; SMN2 (0.60) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL565787 | 0.81 | TDP1 (0.54) | ALDH1A1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL4541169 | 0.80 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2AHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9034372-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8962015-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | SDG, INC. | 2011-06-09 | — | — | US | disclosed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | ALDH1A1 2309/4885CA12 3452/4885CA2 2040/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | ALDH1A1 3404/4885CA12 3441/4885CA2 2092/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | ALDH1A1 4198/4885CA12 2944/4885CA2 3633/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | ALDH1A1 1477/4885CA12 1226/4885CA2 3952/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | ALDH1A1 2309/4885CA12 3452/4885CA2 2040/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | ALDH1A1 2309/4885CA12 3452/4885CA2 2040/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | ALDH1A1 4129/4885CA12 942/4885CA2 1696/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | ALDH1A1 3085/4885CA12 2422/4885CA2 1569/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | ALDH1A1 4198/4885CA12 2944/4885CA2 3633/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | ALDH1A1 4198/4885CA12 2944/4885CA2 3633/4885 |
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | INSR, INSRR, IAPP | ALDH1A1 4252/4885CA12 1126/4885CA2 1276/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | ALDH1A1 1477/4885CA12 1226/4885CA2 3952/4885 |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | ALDH1A1 4198/4885CA12 2944/4885CA2 3633/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | ALDH1A1 4252/4885CA12 1126/4885CA2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.